Peptide-based medications such as semaglutide, the active compound in Ozempic and Wegovy, have long encountered stability issues due to their linear molecular structures. A team at the University of Utah has explored an enzymatic method that could address these limitations by transforming these drugs into more durable, ring-shaped molecules through a process called macrocyclization. However, the transition from laboratory findings to practical medical use involves significant challenges.
The Science Behind the Ring
Peptides, which serve as the foundation for drugs like semaglutide, present unique engineering difficulties. Their reactive chemical properties make them effective in biological systems but also leave them vulnerable to rapid degradation. As officials involved in the research noted, peptides can be challenging to modify with precision because of their reactive groups, though these same properties contribute to their biological effectiveness.
The study, published in ACS Bio & Med Chem Au, highlights PapB’s role as an enzymatic tool capable of linking the ends of a peptide into a ring structure. Unlike conventional chemical methods, which often require additional sequences or complex modifications, PapB facilitates this process by forming a sulfur-carbon bond known as a thioether. This results in a more compact molecular structure that researchers suggest may enhance drug stability and improve targeting within the body.
Ring-shaped peptides have been studied for their potential benefits, including increased resistance to enzymatic breakdown. Their circular structure may allow them to remain active in the body longer than linear peptides and interact more precisely with biological targets. This could lead to more consistent dosing and fewer side effects. For medications like GLP-1 drugs, which currently require frequent administration, such improvements could be meaningful—provided the method proves viable at scale.
From Lab to Pharmacy: The Unanswered Questions
The University of Utah team has taken steps to advance their research toward practical applications. Karsten Eastman and chemistry professor Vahe Bandarian co-founded Sethera Therapeutics in 2023 to develop their findings further. The company’s PolyMacrocyclic Peptide (pMCP) Discovery Platform has garnered recognition, including a recent university award and funding from the National Institutes of Health. Officials involved in the project described the enzymatic method as a way to modify peptides with high precision, potentially enabling a new class of peptide therapeutics.
Despite these advancements, laboratory success does not guarantee clinical effectiveness. While experiments have demonstrated PapB’s ability to create ring structures from GLP-1-like peptides, even those with nonstandard components, its performance in human trials remains untested. Peptide therapeutics have a history of promising early results that do not always translate into successful medical treatments. Scaling production, maintaining consistent quality, and navigating regulatory requirements present substantial hurdles, and the timeline for overcoming them is uncertain.
At this stage, the discovery of PapB represents a step forward in peptide modification techniques rather than a confirmed medical advancement. The enzyme offers a more efficient way to alter peptide structures, but it does not ensure that these modifications will result in improved drugs. Its ability to function without additional sequences is an advantage, though it is only one factor in a complex development process. Questions remain about whether the method can be adapted for large-scale manufacturing or applied to other peptide-based medications.
What to Watch in Peptide Therapeutics
The potential impact of Sethera Therapeutics’ work extends beyond the company itself. GLP-1 drugs have already made significant strides in treating diabetes and obesity, but their limitations—such as frequent dosing, high costs, and side effects—highlight the need for further innovation. If the PapB method delivers on its early promise, it could contribute to a new generation of peptide-based drugs that are more stable, effective, and easier to produce. However, this outcome is far from certain.
For patients and healthcare providers, the key question is whether this research will lead to tangible improvements in existing medications like Ozempic and Wegovy. The answer depends on how quickly Sethera can progress from laboratory experiments to clinical trials and whether those trials yield positive results. The company’s recent funding and recognition indicate progress, but drug development is a lengthy and unpredictable process.
The discovery of PapB also reflects a broader trend in peptide engineering. Traditional chemical methods, while effective, are often complex and costly. Enzymatic approaches like PapB could provide a more scalable alternative, reducing the need for precise and expensive modifications. If successful, this method might be applied to other peptide-based drugs, expanding treatment options for conditions beyond diabetes and obesity.
For now, the focus should remain on whether Sethera can demonstrate the practical viability of its platform. The next phases—preclinical testing, regulatory submissions, and human trials—will determine whether PapB represents a meaningful scientific advancement or remains an experimental curiosity. Until then, its potential remains just that: potential.
